Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.

Maxime Beaulieu Alexandre GaymardClément MassonnaudNathan Peiffer SmadjaMaude Bouscambert-DuchampGuislaine CarcelainGuillaume Lingas France Mentré Florence Ader Maya Hites Pascal Poignard Jeremie Guedj

Published in: The Journal of antimicrobial chemotherapy (2024)

Hospitalized patients treated with Evusheld had a shorter median time to SARS-CoV-2 viral clearance. As Evusheld antiviral activity is mediated by the level of neutralization activity, its impact on viral clearance varies largely according to the variant of infection.

Keyphrases

sars cov
phase iii
respiratory syndrome coronavirus
phase ii
clinical trial
open label
double blind
small molecule
placebo controlled
coronavirus disease
high throughput
copy number
gene expression